<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02515643</url>
  </required_header>
  <id_info>
    <org_study_id>PR(AG)219/2014</org_study_id>
    <nct_id>NCT02515643</nct_id>
  </id_info>
  <brief_title>Contribution of Renal Function to Endothelial Dysfunction in Living Kidney Donors and Transplant Recipients</brief_title>
  <acronym>CONFUCIUS</acronym>
  <official_title>Estimating the Contribution of Renal Function to Endothelial Dysfunction by a Two-cohort Study: Living Kidney Donors and Their Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari Vall d'Hebron Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Teva Pharmaceutical Industries, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitari Vall d'Hebron Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endothelial dysfunction one-year after transplantation mainly depends on&#xD;
      transplant-associated factors and only marginally on reduced renal function.&#xD;
&#xD;
      OBJETIVES Primary objective Estimate the contribution of renal dysfunction to endothelial&#xD;
      dysfunction in two cohorts of patients, living kidney donors and their transplant recipients.&#xD;
&#xD;
      Secondary objectives&#xD;
&#xD;
      To evaluate in both cohorts of patients before and after nephrectomy/transplantation the&#xD;
      evolution of the following parameters:&#xD;
&#xD;
        1. Renal function (iohexolGFR, proteinuria/microalbuminuria).&#xD;
&#xD;
        2. Blood pressure (24 h ambulatory blood pressure measurement)&#xD;
&#xD;
        3. Surrogate variables of subclinical atherosclerosis (carotid ultrasound, ankle-brachial&#xD;
           index, pulse wave velocity).&#xD;
&#xD;
      DESIGN Non-interventional, prospective, multicenter, longitudinal study of two cohorts:&#xD;
      living kidney donors and their transplant recipients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HYPOTHESIS&#xD;
&#xD;
      BACKGROUND: Chronic kidney disease (CKD) is associated with endothelial dysfunction, but the&#xD;
      link between cardiovascular risk and CKD is difficult to establish because other conditions&#xD;
      such as diabetes, hypertension and transplant-related factors are present in these patients.&#xD;
      Living donors are healthy individuals that represent a near-ideal experimental model of CKD&#xD;
      since they undergo a time-defined reduction of GFR after nephrectomy in the absence of other&#xD;
      confounding factors present in patients with mild to moderate CKD.&#xD;
&#xD;
      HYPOTHESIS: Reduction of GFR after donation is associated with increased while renal&#xD;
      transplantation is associated with reduced endothelial dysfunction markers.&#xD;
&#xD;
      AIM: To prospectively evaluate biomarkers of endothelial dysfunction and surrogate variables&#xD;
      of subclinical atherosclerosis in a cohort of living kidney donors before and one year after&#xD;
      donation and in their recipients before and one year after transplantation.&#xD;
&#xD;
      PATIENTS AND METHODS: In two cohorts of 60 living kidney donors (1 month before and 1 year&#xD;
      after donation) and in their 60 renal transplant recipients (1 month before and 1 year after&#xD;
      transplantation) the following variables will be recorded: iohexol glomerular filtration rate&#xD;
      (GFR), proteinuria, microalbuminuria, insulinemia, oral glucose tolerance test, total and&#xD;
      LDL/HDL cholesterol, number of carotid plaques and intima-media thickness, carotid-femoral&#xD;
      pulse wave velocity, ankle-brachial index, 24-hours ambulatory monitoring of blood pressure.&#xD;
      The following biomarkers of endothelial dysfunction and subclinical inflammation will be&#xD;
      determined: SVCAM-1, PTX3, ICAM-1, von Willebrand factor, E-selectin, platelet/endothelial&#xD;
      cell adhesion molecule (PECAM1), interleukin 6 (IL-6), soluble receptor of tumor necrosis&#xD;
      factor (sTNFR1 and sTNFR2), high sensitive C reactive protein (hs-CRP) and soluble TNF-like&#xD;
      weak inducer of apoptosis (sTWEAK).&#xD;
&#xD;
      EXPECTED RESULTS. In healthy subjects decrease of renal function after living donation will&#xD;
      be associated with increased endothelial dysfunction markers. On the contrary, after&#xD;
      transplantation a decrease of endothelial dysfunction markers will be observed. Despite at&#xD;
      one year both cohorts of patients will have a similar GFR, the investigators expect that&#xD;
      amelioration of endothelial dysfunction in transplants will be higher than worsening of&#xD;
      endothelial dysfunction in their donors. Thus, the study of these two cohorts will allow&#xD;
      estimating the contribution of renal dysfunction per se and transplant-associated&#xD;
      comorbidities to endothelial dysfunction in chronic kidney disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentual change of sVCAM</measure>
    <time_frame>1 year</time_frame>
    <description>Biomarker of endothelial dysfunction: Soluble VCAM (vascular cell adhesion molecule). Determination of serum levels by Luminex. Percentual change between baseline and 1 year levels.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glomerular filtration rate</measure>
    <time_frame>1 year</time_frame>
    <description>Renal function will be estimated before donation by iohexol clearance and expressed as mL/min/1.73 m2 in donors and at 1 year in donors and recipients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microalbuminuria</measure>
    <time_frame>1 year</time_frame>
    <description>Microalbuminuria (mg/g creatinine) will be determined before donation and at 1 year in donors and at 1 year in transplant recipients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure (24 h ambulatory blood pressure measurement)</measure>
    <time_frame>1 year</time_frame>
    <description>Ambulatory blood pressure monitoring (mm Hg) with overnight-automated ABPM monitor (Spacelab 90207; Spacelabs Healthcare,USA) with appropriate cuff sizes for each patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of carotid plaques and carotid intima-media thickness</measure>
    <time_frame>1 year</time_frame>
    <description>Atherosclerotic burden: carotid ultrasound to determine the number of plaques and intima-media thickness will be held in both carotid arteries with a high-frequency (8-12 MHz) linear transducer (ESAOTE, 7300, Florence, Italy),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse wave velocity.</measure>
    <time_frame>1 year</time_frame>
    <description>Carotid-femoral pulse wave velocity (m/s) will be measured by pulse tonometry (Sphingmocor Atcor, EM3, Australia).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentual change of sICAM</measure>
    <time_frame>1 year</time_frame>
    <description>Biomarker of endothelial dysfunction: Soluble ICAM (intercellular adhesion molecule). Determination of serum levels by Luminex. Percentual change between baseline baseline and 1 year levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentual change of PECAM</measure>
    <time_frame>1 year</time_frame>
    <description>Biomarker of endothelial dysfunction: PECAM (platelet/endothelial cell adhesion molecule). Determination of serum levels by Luminex. Percentual change between baseline baseline and 1 year levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentual change of vWF</measure>
    <time_frame>1 year</time_frame>
    <description>Biomarker of endothelial dysfunction: vWF (von Willebrand factor). Determination of serum levels by Luminex. Percentual change between baseline baseline and 1 year levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentual change of E-selectin</measure>
    <time_frame>1 year</time_frame>
    <description>Biomarker of endothelial dysfunction: Soluble E-selectin. Determination of serum levels by Luminex.Percentual change between baseline baseline and 1 year levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentual change of PTX3</measure>
    <time_frame>1 year</time_frame>
    <description>Biomarker of endothelial dysfunction: PTX3 (pentraxin). Determination of serum levels by ELISA. Percentual change between baseline baseline and 1 year levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentual change of hs-CRP</measure>
    <time_frame>1 year</time_frame>
    <description>Biomarker of subclinical inflammation: hs-CRP (high sensitive C reactive protein). Determination of serum levels by nephelometry. Percentual change between baseline baseline and 1 year levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentual change of IL-6</measure>
    <time_frame>1 year</time_frame>
    <description>Biomarker of subclinical inflammation: IL-6 IL-6 (interleukin 6). Determination of serum levels by Luminex. Percentual change between baseline baseline and 1 year levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentual change of sTNFR1 and sTNFR2</measure>
    <time_frame>1 year</time_frame>
    <description>Biomarker of subclinical inflammation: sTNFR1 and sTNFR2 (soluble tumor necrosis factor receptor). Determination of serum levels by Luminex. Percentual change between baseline baseline and 1 year levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentual change of sTWEAK</measure>
    <time_frame>1 year</time_frame>
    <description>Biomarker of subclinical inflammation: sTWEAK (soluble TNF-like weak inducer of apoptosis). Determination of serum levels by ELISA. Percentual change between baseline baseline and 1 year levels.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Disorder Related to Renal Transplantation</condition>
  <condition>Chronic Kidney Disease</condition>
  <condition>Endothelial Dysfunction</condition>
  <arm_group>
    <arm_group_label>Endothelial dysfunction in Cohort 1</arm_group_label>
    <description>Assessment of endothelial dysfunction in healthy subjects who will undergo a nephrectomy as part of the living donor program at each participating center.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endothelial dysfunction in Cohort 2</arm_group_label>
    <description>Assessment of endothelial dysfunction in renal transplant recipients from cohort 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Endothelial dysfunction</intervention_name>
    <description>One month before surgery and one year after, the following procedures will be performed in donors and recipients:&#xD;
Blood samples will be obtained for the measurement of endothelial dysfunction and low grade inflammation markers.&#xD;
Atherosclerotic burden: carotid ultrasound to determine the number of plaques and intima-media thickness, carotid-femoral pulse wave velocity (m/s) will be performed by pulse tonometry.&#xD;
Ambulatory blood pressure monitoring with overnight-automated ABPM monitor&#xD;
Estimation of glomerular filtration rate by Iohexol method</description>
    <arm_group_label>Endothelial dysfunction in Cohort 1</arm_group_label>
    <arm_group_label>Endothelial dysfunction in Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Cohort 1&#xD;
&#xD;
        Healthy subjects who will undergo a nephrectomy as part of the living donor program at each&#xD;
        participating center.&#xD;
&#xD;
        Cohort 2&#xD;
&#xD;
        Renal transplant recipients from cohort 1&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria cohort 1:&#xD;
&#xD;
          -  No history of familiar nephropathies and/other diseases that may increase the risk for&#xD;
             renal disease in the future.&#xD;
&#xD;
          -  Donor age ≥ 18 years&#xD;
&#xD;
          -  Isotopic GFR &gt; 80 ml/min/1.73m2&#xD;
&#xD;
          -  Microalbuminuria&lt; 30 mg/g&#xD;
&#xD;
          -  Normal urinary sediment&#xD;
&#xD;
          -  Normal blood pressure defined as &lt;120/90 mmHg and without other risk factors for&#xD;
             cardiovascular disease, and with good/normal kidney function or well-controlled&#xD;
             hypertension with one anti-hypertensive drug,&#xD;
&#xD;
          -  No previous history of diabetes including gestational diabetes and fasting glucose &lt;&#xD;
             126 mg/dl and 2h serum glucose after 75 g oral glucose tolerance test &lt; 200 mg/dl&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Inclusion criteria cohort 2:&#xD;
&#xD;
          -  Chronic kidney disease stage 5&#xD;
&#xD;
          -  Negative complement dependent lymphocytotoxicity donor-recipient cross-match.&#xD;
&#xD;
          -  Informed signed consent&#xD;
&#xD;
        Exclusion Criteria cohort 1:&#xD;
&#xD;
          -  History of cancer except non-melanoma cutaneous neoplasia&#xD;
&#xD;
          -  History of vasculitis (e.g. lupus), sarcoidosis, gastrointestinal inflammatory&#xD;
             diseases, autoimmune-disease&#xD;
&#xD;
          -  History of major cardiovascular events&#xD;
&#xD;
          -  History of deep vein thrombosis or pulmonary embolism.&#xD;
&#xD;
          -  Active infection including hepatitis B, C and HIV infections.&#xD;
&#xD;
          -  Anatomic vascular variants precluding laparoscopic nephrectomy&#xD;
&#xD;
          -  Renal stones except a solitary lithiasis&lt; 1.5 cm once metabolic disorders are ruled&#xD;
             out&#xD;
&#xD;
          -  Major psychiatric disorders&#xD;
&#xD;
          -  Active alcohol, tobacco or drug abuse&#xD;
&#xD;
          -  Obesity defined as body mass index &gt; 35 kg/m2.&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
        Exclusion criteria cohort 2:&#xD;
&#xD;
          -  Glomerulonephritis with high recurrence rate after transplantation (focal segmental&#xD;
             glomerulosclerosis and type II membranoproliferative glomerulonephritis)&#xD;
&#xD;
          -  Severe aortoiliac atherosclerosis precluding transplantation&#xD;
&#xD;
          -  Major psychiatric disorders&#xD;
&#xD;
          -  Alcohol and drug abuse&#xD;
&#xD;
          -  Active infection&#xD;
&#xD;
          -  Patients requiring desensitization treatment before transplantation.&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesc Moreso, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Vall d'Hebron</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francesc Moreso, MD, PhD</last_name>
    <phone>+34932746079</phone>
    <email>fjmoreso@vhebron.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario Canarias</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <state>Islas Canarias</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Armando Torres, MD, PhD</last_name>
      <phone>+34 922 31 93 38</phone>
      <email>atorres@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ana Gonzalez-Rinne, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Esteban Porrini, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julio Pascual, MD, PhD</last_name>
      <phone>+34 932 48 31 62</phone>
      <email>99176@parcdesalutmar.cat</email>
    </contact>
    <investigator>
      <last_name>Marta Crespo, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron Research Institute</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesc Moreso, MD, PhD</last_name>
      <phone>+34 93 274 60 79</phone>
      <email>fjmoreso@vhebron.net</email>
    </contact>
    <investigator>
      <last_name>Francesc Moreso, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Seron, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manel Perello, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carme Cantarell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joana Sellarés, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Natalia Ramos, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario Carlos Haya</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Domingo Hernandez, MD, PhD</last_name>
      <phone>+34 951 29 11 74</phone>
      <email>domingohernandez@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Mercedes Cabello</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>July 10, 2015</study_first_submitted>
  <study_first_submitted_qc>August 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2015</study_first_posted>
  <last_update_submitted>March 27, 2017</last_update_submitted>
  <last_update_submitted_qc>March 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

